|Bid||35.920 x 900|
|Ask||35.930 x 1000|
|Day's Range||35.730 - 36.220|
|52 Week Range||32.320 - 39.430|
|PE Ratio (TTM)||9.99|
|Forward Dividend & Yield||1.36 (3.74%)|
|1y Target Est||N/A|
The corporate tax cut passed by U.S. President Donald Trump and fellow Republicans that was in part designed to help dissuade U.S. companies from moving profits overseas may instead make the practice a lot more rewarding. The new tax bill cuts the overall corporate tax rate to 21 percent, and allows income from overseas to be taxed at about half that rate – to as low as 10 percent. AbbVie Inc. is a case in point.
Big Pharma is struggling to keep up with the rest of the market this year as tepid revenue, growth, the expiration of key patents, and the likelihood of the government imposing tighter cost controls hold back its performance prospects. Earlier this month, while the broader S&P 500 was yielding just 2%, the dividend yield on the big drug companies in the index was nearly a full percentage point higher at 2.9%.
Investors continue to pour money into passive vehicles such as indexed mutual funds and exchange-traded funds. However, good old-fashioned stock picking and asset allocation with a human touch still rules in some areas - including in the well-trodden world of blue-chip stocks. After all, actively managed mutual funds run by professional portfolio managers still dwarf their passive cousins. At the end of 2017, actively managed funds had a total of $11.4 trillion in assets under management, according to Morningstar. Passive funds and ETFs controlled $6.7 trillion in assets. As we've noted before, the "smart money" doesn't always live up to the high fees and hype, but it's worth keeping tabs on what they're doing nonetheless. That's even more true for actively managed mutual funds. After all, they comprise a much larger swath of institutional investor dollars. Using data from Morningstar Direct, we were able to discover which blue-chip stocks are most widely held by the biggest actively managed U.S. mutual funds. In other words, these are the 25 most popular stock picks among professional portfolio managers. Not every one of the following stocks is necessarily a buy at current levels, but it's fair to say that they are all superstar companies. And the most popular pick of all probably will surprise you. SEE ALSO: 53 Best Dividend Stocks for 2018 and Beyond
Now, Sprout Pharmaceuticals will make a second attempt to sell the drug but using a different method. Most importantly, Sprout will sell the drug for just $400, a 50% markdown from Valeant’s selling price. Both companies have an interest in getting patients prescribed on Addyi.
ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, reported on Thursday positive early results from two late-stage trials testing its two-drug regimen in patients new to HIV treatment relative to a three-drug regimen. GlaxoSmithKline shares rose 2.4% in premarket trade on Thursday after the news. It plans to file for regulatory approvals of the two-drug regimen, composed of the drugs dolutegravir and lamivudine, later this year, and also has plans to present full results at an upcoming scientific meeting.
Let’s be honest: with an income stream like that, backed by household names like Pfizer and AT&T—more on these two stocks below—you’d leap at the chance, right? Funny thing is, for a brief, shining moment in the not-so-distant past (early March 2009), many blue chips actually did deliver payouts of 7%, 10% and more. You needed nerves of steel to plunge in while everyone else was sprinting from the worst market crash since 1929.
Dividends play a key role in compounding returns over time and can form a large part of our portfolio return. Pfizer Inc (NYSE:PFE) has returned to shareholders over the pastRead More...
December 4, 2006 proved to be a fateful day for Pfizer–the day when it announced that the highly touted cholesterol modifying drug, torcetrapib, was being dropped from development. This drug had potent cholesterol modifying properties: doubling a heart patient’s HDL-c while simultaneously lowering LDL-c by 20% (on top of Lipitor’s 40% LDL-c lowering effect). When patients took torcetrapib in combination with Lipitor, their lipoprotein levels essentially normalized, results that were unprecedented.
Whether it's a steady source of income, capital appreciation to grow your nest egg, or both, these three dividend stocks look like smart choices.
On June 7, Pfizer (PFE) announced that the FDA and the European Medicines Agency (or EMA) provided updates on the regulatory submissions of Talazoparib for the treatment of locally advanced or metastatic breast cancer. In this article, we’ll examine the drug, regulatory submissions, and clinical trials related to the drug.
Shares of Lilly (LLY) and Pfizer (PFE) have eked out small year-to-date gains, but the stocks are higher Friday, thanks to bullish notes from Cantor Fitzgerald. Analyst Louise Chen initiated coverage of both stocks at Overweight, with a $100 price target for Lilly and $45 price target for Pfizer. For Lilly, she highlights the growth prospects for the company's main drugs, Trulicity, Jardiance, Taltz and Verzenio, and she's also enthusiastic about its pipeline assets, which she believes are underappreciated, especially in the pain category.
Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.
The company is pushing into clinical trials for its experimental broad-spectrum vaccine against a bacterium that causes pneumonia and bloodstream infections.
Pfizer (PFE) presented its final data on dacomitinib at the 54th Annual Meeting of the American Society of Clinical Oncology (or ASCO) on June 4.
The 54th Annual Meeting of the American Society of Clinical Oncology (or ASCO) was held in Chicago from June 1 to June 5.